{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:12:40Z","timestamp":1781881960785,"version":"3.54.5"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["2021\/10265-8"],"award-info":[{"award-number":["2021\/10265-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cpet.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T18:19:07Z","timestamp":1720117147000},"page":"475-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radioligand Therapy in Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Ludmila Santiago","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto C.","family":"Delgado Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Cabral","family":"Heringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"de Souza Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba","family":"Etchebehere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib2","doi-asserted-by":"crossref","first-page":"101510","DOI":"10.1016\/j.beha.2023.101510","article-title":"Hodgkin lymphoma: focus on evolving treatment paradigms","volume":"36","author":"Roswarski","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.003_bib4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archsurg.1986.01400100031005","article-title":"A\u00a0comparison of staging methods for Hodgkin's disease in children","volume":"121","author":"Lally","year":"1986","journal-title":"Arch Surg"},{"issue":"8","key":"10.1016\/j.cpet.2024.05.003_bib5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/RLU.0000000000001718","article-title":"Multicenter comparison of contrast-enhanced FDG PET\/CT and 64-slice multi-detector-row CT for initial staging and response evaluation at the end of treatment in patients with lymphoma","volume":"42","author":"G\u00f3mez Le\u00f3n","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0001-2998(84)80016-1","article-title":"Labeled cells in the investigation of hematologic disorders","volume":"14","author":"Alavi","year":"1984","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cpet.2006.04.004","article-title":"Historical overview and current state of art in diagnosis and treatment of Hodgkin's and Non-Hodgkin's Lymphoma","volume":"1","author":"de Vos","year":"2006","journal-title":"Pet Clin"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/jcp.38.11.1247","article-title":"Fertility in young men and women after treatment for lymphoma: a study of a population","volume":"38","author":"King","year":"1985","journal-title":"J\u00a0Clin Pathol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib9","first-page":"1015","article-title":"Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease","volume":"66","author":"Cunningham","year":"1982","journal-title":"Cancer Treat Rep"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib10","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/1097-0142(19811201)48:11<2386::AID-CNCR2820481109>3.0.CO;2-B","article-title":"Second malignant neoplasms in patients treated for Hodgkin's disease with radiotherapy or radiotherapy and chemotherapy","volume":"48","author":"Nelson","year":"1981","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development - progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann Med Surg (Lond)"},{"issue":"3 Suppl 3","key":"10.1016\/j.cpet.2024.05.003_bib12","first-page":"23","article-title":"Monoclonal antibodies in the treatment of hematopoietic malignancies","volume":"25","author":"Houghton","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1016\/j.cpet.2024.05.003_bib13","series-title":"Impact of treatment sequencing on outcomes and costs in relapsed low-grade or follicular B-cell non-Hodgkin lymphoma","author":"Carson","year":"2015"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clml.2023.01.010","article-title":"Yttrium-90 ibritumomab is cost-effective compared to bendamustine\u00a0+ rituximab in low-grade lymphomas","volume":"23","author":"Alhaj Moustafa","year":"2023","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.cpet.2024.05.003_bib17","series-title":"Encyclopedia of cancer","article-title":"Diabody","author":"Ozaki","year":"2011"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"issue":"16","key":"10.1016\/j.cpet.2024.05.003_bib19","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.7150\/thno.56639","article-title":"A\u00a0perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma","volume":"11","author":"Bolcaen","year":"2021","journal-title":"Theranostics"},{"issue":"16","key":"10.1016\/j.cpet.2024.05.003_bib20","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.3390\/molecules27165231","article-title":"Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges","volume":"27","author":"Salih","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijrobp.2008.05.029","article-title":"Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation","volume":"72","author":"Dahle","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.003_bib23","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1054\/bjoc.2000.1453","article-title":"Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells","volume":"83","author":"Aurlien","year":"2000","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.cpet.2024.05.003_bib24","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2010-05-282327","article-title":"Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease","volume":"116","author":"Park","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib25","first-page":"544","article-title":"An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients","volume":"139","author":"Thakral","year":"2014","journal-title":"Indian J Med Res"},{"issue":"19 Pt 2","key":"10.1016\/j.cpet.2024.05.003_bib26","doi-asserted-by":"crossref","first-page":"7109s","DOI":"10.1158\/1078-0432.CCR-1004-0009","article-title":"Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods","volume":"11","author":"Sharkey","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10 Suppl","key":"10.1016\/j.cpet.2024.05.003_bib27","first-page":"3292s","article-title":"Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-\/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma","volume":"5","author":"Juweid","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"10 Suppl","key":"10.1016\/j.cpet.2024.05.003_bib28","first-page":"3304s","article-title":"Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies","volume":"5","author":"Behr","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.cpet.2024.05.003_bib29","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Lind\u00e9n","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.cpet.2024.05.003_bib30","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin's lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib31","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(16)30168-5","article-title":"Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial","volume":"4","author":"Kraeber-Bodere","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.cpet.2024.05.003_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","article-title":"Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody","volume":"7","author":"Press","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.117.195347","article-title":"Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-radionuclide conjugate 177Lu-lilotomab satetraxetan","volume":"59","author":"Blakkisrud","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"23","key":"10.1016\/j.cpet.2024.05.003_bib34","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/1078-0432.CCR-19-1567","article-title":"Phase I study of a CD45-targeted antibody-radionuclide conjugate for high-risk lymphoma","volume":"25","author":"Cassaday","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib35","doi-asserted-by":"crossref","first-page":"57.e1","DOI":"10.1016\/j.bbmt.2020.09.021","article-title":"Yttrium-90 anti-CD45 immunotherapy followed by autologous hematopoietic cell transplantation for relapsed or refractory lymphoma","volume":"27","author":"Tuazon","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.cpet.2024.05.003_bib36","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.7150\/thno.19119","article-title":"[177Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent","volume":"7","author":"Schottelius","year":"2017","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2967\/jnumed.118.210997","article-title":"Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma","volume":"60","author":"Lapa","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.122.264207","article-title":"C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma","volume":"64","author":"Buck","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib39","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib40","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.003_bib41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium-90 Ibritumomab , IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib42","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib43","first-page":"513","article-title":"131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital","volume":"18","author":"Turner","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"issue":"9","key":"10.1016\/j.cpet.2024.05.003_bib44","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A\u00a0phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","article-title":"Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma","volume":"35","author":"Shimoni","year":"2007","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.003_bib47","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"27","author":"Winter","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.003_bib48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ajh.25818","article-title":"A\u00a0phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma","volume":"95","author":"Chow","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.cpet.2024.05.003_bib49","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/j.clml.2023.05.011","article-title":"Results of a phase II trial of allogeneic hematopoietic stem cell transplantation using 90Y-ibritumomab (Zevalin) in combination with fludarabine and melphalan in patients with high-risk B-cell non-Hodgkin's lymphoma","volume":"23","author":"Mei","year":"2023","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.003_bib50","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue","volume":"16","author":"Liu","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib51","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults\u00a0> or\u00a0= 60 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2024.05.003_bib52","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbmt.2014.02.004","article-title":"Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age \u2265 60 years with B cell lymphoma","volume":"20","author":"Gopal","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib53","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00277-011-1199-y","article-title":"Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue","volume":"90","author":"Hohloch","year":"2011","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.cpet.2024.05.003_bib54","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A\u00a0phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.cpet.2024.05.003_bib55","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","article-title":"High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation","volume":"26","author":"Devizzi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib56","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/bmt.2012.62","article-title":"Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma","volume":"47","author":"Bethge","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","article-title":"Fractionated \u2079\u2070Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria","volume":"32","author":"Illidge","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib59","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12695","article-title":"Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study","volume":"164","author":"Ibatici","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.003_bib60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","author":"Samaniego","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cpet.2024.05.003_bib61","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2024.05.003_bib62","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/sj.bjc.6603166","article-title":"Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"94","author":"Buchegger","year":"2006","journal-title":"Br J Cancer"},{"issue":"27","key":"10.1016\/j.cpet.2024.05.003_bib63","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","article-title":"Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"24","author":"Leahy","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.003_bib64","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","article-title":"Phase 1\/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cpet.2024.05.003_bib65","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib66","first-page":"478","article-title":"Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia","volume":"19","author":"Schilder","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"issue":"23","key":"10.1016\/j.cpet.2024.05.003_bib67","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","article-title":"The radioisotope contributes significantly to the activity of radioimmunotherapy","volume":"10","author":"Davis","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.003_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","article-title":"Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma","volume":"5","author":"Gordon","year":"2004","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib69","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cncr.23236","article-title":"A\u00a0phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 Ibritumomab for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma","volume":"112","author":"Zinzani","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.cpet.2024.05.003_bib70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clml.2011.04.009","article-title":"Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 Ibritumomab and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma","volume":"11","author":"Karmali","year":"2011","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib71","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90 Ibritumomab in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10428194.2021.1971216","article-title":"A\u00a0randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results","volume":"63","author":"L\u00f3pez-Guillermo","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib74","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A\u00a0phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cpet.2024.05.003_bib75","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2967\/jnumed.109.067587","article-title":"Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial","volume":"50","author":"Delaloye","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"32","key":"10.1016\/j.cpet.2024.05.003_bib76","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib77","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdm560","article-title":"A\u00a0phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients","volume":"19","author":"Zinzani","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib78","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1038\/bcj.2016.29","article-title":"Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results","volume":"6","author":"Stefoni","year":"2016","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib79","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/10428194.2011.635857","article-title":"Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma","volume":"53","author":"Yang","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000368291","article-title":"Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant","volume":"133","author":"Arnason","year":"2015","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib83","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cpet.2024.05.003_bib84","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2967\/jnumed.122.265199","article-title":"Theranostics in hematooncology","volume":"64","author":"Buck","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib85","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41401-020-00511-5","article-title":"Feasibility study of 68Ga-labeled CAR T cells for in\u00a0vivo tracking using micro-positron emission tomography imaging","volume":"42","author":"Wang","year":"2021","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.cpet.2024.05.003_bib86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semnuclmed.2009.12.002","article-title":"Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy","volume":"40","author":"Sharkey","year":"2010","journal-title":"Semin Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.05.003_bib87","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after Ibritumomab radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.003_bib88","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41409-023-02025-0","article-title":"Yttrium-90 ibritumomab tiuxetan plus ATG\/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma","volume":"58","author":"Othman","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/bjh.17758","article-title":"Long-term efficacy and safety of chemotherapy-free first-line iodine-131-rituximab radioimmunotherapy of follicular lymphoma","volume":"196","author":"Kesavan","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.cpet.2024.05.003_bib90","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-022-04781-3","article-title":"90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years","volume":"101","author":"Rieger","year":"2022","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.cpet.2024.05.003_bib91","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clml.2022.03.004","article-title":"Real world long-term follow-up experience with yttrium-90 ibritumomab tiuxetan in previously untreated patients with low-grade follicular lymphoma and marginal zone lymphoma","volume":"22","author":"Alhaj Moustafa","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"5","key":"10.1016\/j.cpet.2024.05.003_bib92","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00277-023-05157-x","article-title":"Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study","volume":"102","author":"Choi","year":"2023","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.003_bib93","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A\u00a0phase I study evaluating ibritumomab tiuxetan (Zevalin\u00ae) in combination with bortezomib (Velcade\u00ae) in relapsed\/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma","volume":"53","author":"Beaven","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.003_bib94","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/10428194.2014.914195","article-title":"Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab","volume":"56","author":"Elstrom","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.cpet.2024.05.003_bib95","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1158\/1078-0432.CCR-17-3561","article-title":"Updated results of rituximab pre- and post-BEAM with or without 90Yttrium ibritumomab tiuxetan during autologous transplant for diffuse large B-cell lymphoma","volume":"24","author":"Chahoud","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cpet.2024.05.003_bib96","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cpet.2024.05.003_bib97","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbmt.2016.10.003","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan as part of reduced-intensity conditioning (with melphalan, fludarabine \u00b1 thiotepa) for allogeneic transplantation in relapsed or refractory aggressive B cell lymphoma: a GELTAMO trial","volume":"23","author":"Cabrero","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155685982400049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155685982400049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:39:50Z","timestamp":1778618390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155685982400049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S155685982400049X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.05.003","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioligand Therapy in Lymphoma","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}